Literature DB >> 28357099

Spontaneous regression of hepatocellular carcinoma in a Caucasian male patient: A case report and review of the literature.

Daniel P Noij1, Petrus W G van Der Linden1.   

Abstract

Hepatocellular carcinoma (HCC) is the most common primary hepatic cancer. As it often presents at an advanced stage, it generally has a poor prognosis. Spontaneous regression is a rare finding in HCC, and is often associated with tumour ischemia or a systemic inflammatory response. We herein present the case of a Caucasian patient with spontaneous regression of advanced HCC, not associated with either mechanism. Our patient was a 74-year old Caucasian male who presented with advanced biopsy-proven HCC, with α-fetoprotein levels of >16,600 kU/l. On computed tomography examination, multiple metastases were identified. Due to the poor performance status and as the patient declined treatment, he was referred to a general practitioner for supportive palliative care. Six months later, the patient was alive and feeling well. He had suffered a cerebrovascular accident with ensuing partial hemiparesis, and had been initiated on enalapril, furosemide and curcumin. On re-evaluation, the lung lesions had disappeared, whereas both the liver and peritoneal lesions had decreased in size. Following a review of the literature, the conclusion was that this case of spontaneous regression of advanced HCC was not caused by ischemia, inflammation, or any other previously reported mechanism. Further research is required to elucidate the mechanisms underlying spontaneous regression of HCC.

Entities:  

Keywords:  European Continental Ancestry Group; case report; curcumin; hepatocellular carcinoma; spontaneous regression

Year:  2016        PMID: 28357099      PMCID: PMC5351713          DOI: 10.3892/mco.2016.1115

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  14 in total

Review 1.  Spontaneous regression of hepatocellular carcinoma: a systematic review.

Authors:  Susana Oquiñena; Francisco Guillen-Grima; Mercedes Iñarrairaegui; Jose M Zozaya; Bruno Sangro
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-03       Impact factor: 2.566

2.  Effects of antihypertensive drugs on cholesterol metabolism of human mononuclear leukocytes and hepatoma cells.

Authors:  H Naegele; B Behnke; A Gebhardt; M Strohbeck
Journal:  Clin Biochem       Date:  1998-02       Impact factor: 3.281

3.  Statin use and risk of hepatocellular carcinoma.

Authors:  Shih-Wei Lai; Kuan-Fu Liao; Hsueh-Chou Lai; Chih-Hsin Muo; Fung-Chang Sung; Pei-Chun Chen
Journal:  Eur J Epidemiol       Date:  2013-05-17       Impact factor: 8.082

Review 4.  Iron, hemochromatosis, and hepatocellular carcinoma.

Authors:  Kris V Kowdley
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 5.  Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response.

Authors:  Jonathan I Huz; Marcovalerio Melis; Umut Sarpel
Journal:  HPB (Oxford)       Date:  2012-05-15       Impact factor: 3.647

Review 6.  Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Preet Paul Singh; Abha Goyal Singh; Mohammad Hassan Murad; William Sanchez
Journal:  Am J Gastroenterol       Date:  2013-02-05       Impact factor: 10.864

7.  Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy.

Authors:  Abhijeet Kumar; Dung T Le
Journal:  J Clin Oncol       Date:  2014-09-22       Impact factor: 44.544

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.

Authors:  Vikrant V Sahasrabuddhe; Munira Z Gunja; Barry I Graubard; Britton Trabert; Lauren M Schwartz; Yikyung Park; Albert R Hollenbeck; Neal D Freedman; Katherine A McGlynn
Journal:  J Natl Cancer Inst       Date:  2012-11-28       Impact factor: 13.506

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.